1. Introduction
===============

Plexiform angiomyxoid myofibroblastic tumor (PAMT), also known as plexiform fibromyxoma, is a rare mesenchymal neoplasm, recently characterized by Takahashi et al^\[[@R1]\]^ and Miettinen et al^\[[@R2]\]^ following reports from the preimmunohistochemistry (IHC) era probably concerning the same entity.^\[[@R3]--[@R7]\]^ At the best of our knowledge, 59 cases of PAMT (including the present case and 2 uncertain ones) have been reported so far (Table [1](#T1){ref-type="table"} ).^\[[@R1],[@R2],[@R8]--[@R33]\]^ This tumor affects both sexes with a wide age span (7--75 years). It typically arises in the gastric antrum; exceptional extragastric cases have been described in the esophagus, duodenum, jejunum, gallbladder and, possibly, in the colon.^\[[@R22],[@R26],[@R27],[@R30],[@R33]\]^ PAMT characteristically features a plexiform architecture, with myxoid nodules located in the gastric muscularis propria, often ulcerating the overlying mucosa, composed of ovoid cells with indistinct cytoplasm; a prominent capillary network is invariably present. At IHC, PAMT is positive for α-smooth muscle actin (α-SMA) and, sometimes, for desmin and/or caldesmon, consistently with myofibroblastic differentiation. *KIT* and *PDGFRA* are wild type. PAMT pursues a benign course following complete excision by distal gastrectomy. Despite PAMT typical location and plexiform architecture, its rarity and rather vague histology, in a context usually suggestive for GIST (the most frequent gastric mesenchymal tumor^\[[@R34]\]^), can hinder bioptic attempts to achieve a correct preoperative diagnosis. The latter can be further confused by the exceptional feature we herein describe in a PAMT: cytokeratin expression.
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2. Case report
==============

A 47-year-old man presented with a syncopal episode following several months of regurgitation and worsening epigastric discomfort. Routine laboratory tests, electrocardiogram, and chest X-ray were unremarkable. Endoscopy showed a subepithelial lesion in the gastric antrum; the overlying mucosa was focally ulcerated. Endoscopic ultrasound-fine needle tissue acquisition^\[[@R35]\]^ did not yield diagnostic material. Contrast-enhanced computed tomography showed an enhancing 6.5 cm mass bulging into the antral cavity and focally involving the omentum. A distal gastrectomy was performed. Currently, at 10 months' follow-up, the patient is well.

Patient\'s informed consent was obtained for publication of this case. All the tests performed were part of the diagnostic work-up, and followed standard laboratory procedures. This case is not part of a clinical trial or research study. The declaration of Helsinki is thus not applicable and approval of the ethics committee is not required.

Sections from formalin-fixed, paraffin-embedded tumor were stained with hematoxylin and eosin or alcian blue. Pathology revealed a 60-mm reddish gelatinous lobulated antral mass (Fig. [1](#F1){ref-type="fig"}A), involving submucosa, muscularis propria, and subserosa; the overlying mucosa was ulcerated. Histology showed a plexiform tumor composed of cells with ovoid nuclei, indistinct cytoplasms and, occasionally, clear halos, in a myxoid, alcian-positive matrix, sometimes with tiny collagen bundles, with arborizing capillary vessels (Fig. [1](#F1){ref-type="fig"}B and C). Tumor cells were positive for α-SMA (Fig. [1](#F1){ref-type="fig"}D), vimentin (not shown) and, partially, for caldesmon (Fig. [1](#F1){ref-type="fig"}E), desmin and CD10 (not shown); moreover, focal positivity for AE1/AE3 (Fig. [1](#F1){ref-type="fig"}F) and pan-CK KL1 (not shown) was detected. CD117, DOG1, CD34, S100, CAM5.2, CK20, CK7, EMA, p53, CDX2, chromogranin A, synaptophysin, Melan-A, HMB-45, and anaplastic lymphoma kinase (ALK) were all negative (not shown). *KIT* (exons 9, 11, 13, and 17) and *PDGFRA* (exons 12, 14, and 18), amplified using the same primers and polymerase chain reaction conditions described elsewhere,^\[[@R35]\]^ were wild type. These findings rule out GIST, the most common mesenchymal tumor of stomach,^\[[@R34]\]^ and carcinoma, because of both morphology and inconsistent immunophenotype; conversely, they are typical of PAMT, with the exception of the focal CK (AE1/AE3 and KL1) expression, exceptional in this tumor type.

![Pathological findings of the resected mass. (A) The resected specimen revealed a 60 mm lobulated intramural antral mass with a reddish gelatinous cut surface. (B, C) Histology of the tumor showed a plexiform intramural neoplasm displaying an alcian-positive myxoid matrix, with an arborizing capillary network (B, hematoxylin and eosin; C, alcian blue). (D--F) Immunohistochemistry of the tumor showed expression of α-smooth muscle actin (D) and partial positivity for caldesmon (E) (note the positive control of the intensely stained muscularis propria---bottom in D, bottom right in E), and focal positivity for cytokeratins AE1/AE3, sometimes with a perinuclear or a dot-like pattern (F).](medi-95-e4207-g003){#F1}

3. Discussion
=============

In this study, we report the exceptional occurrence of CK expression in a typical PAMT. PAMT, also known as plexiform fibromyxoma, is a myofibroblastic tumor recently fully characterized.^\[[@R1],[@R2]\]^ Probably the same tumor had been previously signaled several times in the pre-IHC era.^\[[@R3]--[@R7]\]^ At the best of our knowledge, 59 PAMTs (including the present case and 2 uncertain ones) have been described in the literature (Table [1](#T1){ref-type="table"} ).^\[[@R1],[@R2],[@R8]--[@R33]\]^ With the caveat due to the limitations in both number of cases and follow up, PAMT appears a benign entity; in fact, neither metastases nor relapses after complete surgical resection have been signaled so far. PAMT is capable of smooth muscle differentiation, as shown by the possible focal expression of caldesmon and desmin.^\[[@R1],[@R21],[@R22],[@R28]\]^As such, PAMT can be expected to occasionally express CKs, since both myofibroblastic and smooth muscle tumors are known to be sometimes able to express these markers.^\[[@R36]\]^ A restrict number of mesenchymal tumors (i.e., synovial sarcoma and epithelial sarcoma) display a true epithelial differentiation, with expression of both low- and high-molecular weight CK isoforms and of other epithelial markers, such as desmoplakins and occludin. Unlike these sarcomas, CK expression found in smooth muscle and myofibroblastic tumors is anomalous and does not reflect genuine epithelial differentiation, involving only a subset of neoplastic cells, mostly with IHC staining limited to a portion only of the cytoplasm, sometimes in a dot-like pattern.^\[[@R37]\]^ This is the case of the herein reported PAMT (Fig. [1](#F1){ref-type="fig"}F). Coherently with the lack of a true epithelial differentiation, EMA IHC resulted negative, as happened in all PAMTs previously tested for this marker^\[[@R10],[@R11],[@R13],[@R18],[@R19],[@R27],[@R30]\]^ with the exception of a focal positivity in a single case reported in the Chinese literature.^\[[@R20]\]^ The presence of a hybrid epithelial--mesenchymal phenotype (so-called "amphicrine pattern") is a feature of epithelial-to-mesenchymal and mesenchymal-to-epithelial cell transitions (MET), phenomena which can be found either in organ development or tumors. With regard to gastrointestinal (GI) mesenchymal tumors, MET has been described in GISTs, apparently with a favorable prognostic role.^\[[@R38]\]^ Given the lack of aggressive behavior in the hitherto reported PAMTs, there is no room for a similar biological role of MET in these tumors.

The morphology of the herein reported PAMT (as happens with PAMT as a whole) does not support a diagnosis of carcinoma, although some carcinomas may show myxoid features.^\[[@R39]\]^ In particular, its typical discohesive architecture excludes most carcinomas with the possible exceptions of poorly cohesive gastric carcinoma and gastric metastasis from a lobular breast cancer. However, the former is ruled out by the lack of atypia in the overlying mucosal epithelium and the latter by the clinical context of the reported tumor (lobular breast cancer is very rare in males). Furthermore, both of these neoplasms are excluded by the detected tumoral immunohistochemical profile.

PAMT must be distinguished from other mesenchymal tumors which can be found in the GI tract. GISTs (which can display myxoid or plexiform features) are typically CD117+ and DOG1+, express CD34 in about 2/3 of cases and mostly bear an activating mutation in either *KIT* or *PDGFRA*.^\[[@R34]\]^ Inflammatory fibroid polyps, although often arising in the gastric antrum, rarely grow deeper than submucosa, typically feature CD34+ spindle cells arranged in an onion-skin pattern around blood vessels, are rich in eosinophils and are often *PDGRA* mutant.^\[[@R40]\]^ Schwannomas, although often displaying areas with a loose texture (so-called "Antoni B areas") and sometimes featuring a plexiform architecture, often exhibit peripheral lymphoid aggregates and are consistently intensely and diffusely S100+. Inflammatory myofibroblastic tumors feature a relevant inflammatory infiltrate which, together with the loosely arranged myofibroblasts in an edematous myxoid background, simulates granulation tissue; moreover, about half of cases display cytoplasmic positivity for ALK protein.^\[[@R41]\]^ Abdominal desmoid-type fibromatoses feature myofibroblasts arranged in long sweeping bundles, set in a collagenous stroma and, although sometimes showing myxoid change, lack a plexiform architecture and are mostly β-catenin positive at nuclear level.^\[[@R42]\]^ Perhaps the gastric mesenchymal tumor which can be more easily confused with PAMT is myxoid leiomyoma, given its positivity for α-SMA, desmin, and caldesmon; however, it usually arises in the cardias or fundus, and is composed of cells with relatively abundant, intensely eosinophilic cytoplasm, with blunt-ended nuclei and intensely and diffusely desmin+ and caldesmon+.^\[[@R43],[@R44]\]^ In females, PAMT must be distinguished from metastatic low-grade endometrial stromal sarcoma (ESS); in fact, progesterone receptor positivity has been exceptionally reported in 2 PAMTs,^\[[@R15],[@R20]\]^ while ESS displays CD10 positivity, can be myxoid and can metastasize to the GI tract; a clinical history negative for gynecological neoplasms and the lack of estrogen and progesterone receptors exclude this entity.^\[[@R11]\]^Table [2](#T2){ref-type="table"} summarizes the differential diagnosis of PAMT.
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Although the PAMT CK expression we report is thus not surprising, given the tissue lineage of this neoplasm, our finding nevertheless contributes to enlarge the known immunophenotypic spectrum of this tumor. In fact, at the best of our knowledge, all PAMTs so far immunohistochemically tested for CK expression resulted negative^\[[@R1],[@R2],[@R11],[@R13],[@R15],[@R16],[@R18],[@R22],[@R24],[@R28],[@R29]\]^ with the exception of the report of focal positivity in a single case from the Chinese literature.^\[[@R20]\]^ But, beyond its descriptive value, the awareness of a possible CK positivity in PAMT is relevant for avoiding possible misinterpretations of PAMT biopsies, especially when dealing with suboptimal amounts of tissue. In fact, under these circumstances, there is the risk of misdiagnosing PAMT as poorly cohesive gastric carcinoma, a neoplasm which can be extensively infiltrative in spite of mucosal lesions endoscopically elusive, potentially leading to dramatic consequences in the management of patients with PAMT.

In conclusion, we demonstrate the possible expression of CK in PAMT, an exceptional finding which, although not surprising considering the tissue lineage of this tumor, can be very relevant in the routine practice of pathologists for avoiding possible misdiagnoses with heavy clinical consequences.

Abbreviations: CK = cytokeratin, IHC = immunohistochemistry, PAMT = plexiform angiomyxoid myofibroblastic tumor.
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